Nevakar's approach to Drug Repositioning: NuPharming™
Nevakar is leading the development and commercialization of pharmaceutical treatments in patients suffering from ophthalmic refractive errors such as myopia.
We are offering differentiated hospital products that improve point of care compliance, simplify drug administration, minimize medication errors, reduce costs to hospitals and improve patient outcomes.
Nevakar is building a new form of pharmaceutical company that is purpose-built to quickly pivot to where we can lead the evolution of medicines with new and/or greater value, at speeds timelier for patients in need.
A HYBRID, INNOVATIVE AND EFFICIENT BUSINESS MODEL
Products developed by big pharma typically generate high value, high margins but carry significant development and commercial risks. While generic companies focus on products that are generally low value, low margin and low risk.
At Nevakar, we believe in leveraging the best of both approaches by utilizing our proprietary NuPharming™ approach to develop and offer products that create significantly higher value and higher margin than generics and lower risk than big pharma. By following this disciplined approach, we have been able to create a scalable portfolio of products.